Domů › Akutní myeloidní leukemie › North Carolina › Durham
Klinické studie Akutní myeloidní leukemie v Durham, NC
33 studií pro Akutní myeloidní leukemie hledá účastníky v lokalitách v Durham a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Duke University Medical Center, Durham
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Probíhá náborFáze 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Probíhá náborFáze 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Probíhá náborFáze 1/2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Probíhá náborFáze 1
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Probíhá náborFáze 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · Vzdálenost 10 mi
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Probíhá náborFáze 3
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · Vzdálenost 10 mi
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Probíhá náborFáze 1
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Probíhá náborFáze 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Probíhá náborFáze 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · Vzdálenost 10 mi
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Probíhá náborFáze 1
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Probíhá náborFáze 1/2
- Research Site, Durham
- Research Site, Chapel Hill · Vzdálenost 10 mi
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Probíhá náborFáze 2
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Probíhá nábor
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · Vzdálenost 10 mi
Registry of Older Patients With Cancer
Probíhá náborObservační studie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Vzdálenost 10 mi
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Probíhá náborFáze 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
A Study of Revumenib and Mezigdomide in People With Leukemia
Probíhá náborFáze 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · Vzdálenost 10 mi
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Probíhá náborFáze 1
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Probíhá náborFáze 1
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · Vzdálenost 10 mi
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Probíhá náborFáze 2
- University of North Carolina, Chapel Hill · Vzdálenost 10 mi
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Probíhá náborFáze 1
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Probíhá náborFáze 1
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
Probíhá nábor
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Probíhá náborObservační studie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1/2
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Probíhá náborVítáni zdraví dobrovolníci
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · Vzdálenost 10 mi
Studie Akutní myeloidní leukemie v jiných městech
- Houston, TX85 studií
- New York City, NY51 studií
- Boston, MA44 studií
- Baldwin Park, CA40 studií
- Seattle, WA40 studií
- Columbus, OH35 studií
- Philadelphia, PA34 studií
- Atlanta, GA30 studií
- Tampa, FL29 studií
- Chicago, IL26 studií
- Portland, OR25 studií
- Miami, FL24 studií
Další studie v Durham
- Rakovina prsu63 studií
- Rakovina (všechny typy)58 studií
- Nemalobuněčný plicní karcinom39 studií
- Mnohočetný myelom37 studií
- Metastatický karcinom33 studií
- Rakovina plic32 studií
- Rakovina prostaty32 studií
- Kolorektální karcinom28 studií
- Chronická lymfocytární leukemie27 studií
- Rakovina vaječníků27 studií
- Srdeční selhání26 studií
- Rakovina slinivky břišní24 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.